



February 6, 2015

## SCYNEXIS Inc.

### Spoke to management: SCY-078 timelines unchanged

**Our view:** Though shares could be pressured the key question is if SCY-078 targeting resistant systemic fungal infections is progressing and that timelines are unchanged. Since data from the i.v. formulation study is due in 2015 and i.v. to oral Phase II in 2016 a pullback could be a buying opportunity.

#### Key points:

**Timeline for data remain unchanged.** For SCY-078 to maximize its commercial opportunity the availability of both an oral and i.v. form would be optimal. We should know in 2015 if an intravenous version is feasible and then in 2016 what data from the Phase II study evaluating the switch from i.v. to oral '078 looks like. This would be followed by an i.v. to oral study with both versions of SCY-078 potentially in patients with resistant organisms.

**Phase II study is evaluating patients with systemic fungal infections, data in 2016.** Patients have invasive candidiasis and will receive intravenous Mycamine (micafungin), an echinocandin, for 5-7 days, followed by either oral fluconazole, an azole, or oral SCY-078 (500 mg or 750 mg), an enfumafungin derivative, for at least 14 days. Patient susceptibility would be evaluated prior to getting fluconazole so there is a chance some could continue on i.v. echinocandin. A step-down to i.v. echinocandins and '078 could prove an alternative for those who cannot receive oral fluconazole. Results are likely in 2016 but could be sooner depending on enrollment timelines. The objective is safety, tolerability for a dose that demonstrates a benefit and not necessarily direct differentiation vs. fluconazole, which is unlikely at this stage as most patients would have responded to micafungin.

**Management transition was previously contemplated.** We spoke to management and understand that SCYX was contemplating a transition from an early, pre-clinical stage to a more clinically experienced team. The new CEO, who will assume the post formally in a few months, has both anti-infectives, anti-fungal, GAIN/ QIDP expertise via the development of cef-avi at Forest Labs so the fit seems reasonable.

**Market opportunity remains attractive.** SCY-078 has a novel mechanism of action targeting life threatening fungal infections resistant to current drugs. SCYX owns 100% and has IP into 2030. Given the current macro environment for antibiotic and anti-fungal drugs, we believe good assets are fundable. Tailwinds include cooperative regulatory authorities, high unmet need in a life-threatening condition, and consolidation in the industry, which has begun with Actavis buying Durata and now Merck buying Cubist.

RBC Capital Markets, LLC

Adnan Butt (Analyst)

(415) 633-8588

adnan.butt@rbccm.com

Jeffrey Takimoto (Associate)

(415) 633-8538

jeffrey.takimoto@rbccm.com

John Chung (Associate)

(415) 633-8620

john.chung@rbccm.com

### Outperform

#### Speculative Risk

NASDAQ: SCYX; USD 9.94

Price Target USD 18.00

#### WHAT'S INSIDE

<input type="checkbox"/> Rating/Risk Change	<input type="checkbox"/> Price Target Change
<input type="checkbox"/> In-Depth Report	<input type="checkbox"/> Est. Change
<input type="checkbox"/> Preview	<input checked="" type="checkbox"/> News Analysis

#### Scenario Analysis\*

Downside Scenario	Current Price	Price Target	Upside Scenario
4.00	9.94	18.00	35.00
↓ 60%		↑ 81%	↑ 252%

\*Implied Total Returns

#### Key Statistics

Shares O/S (MM):	9.7	Market Cap (MM):	96
Dividend:	0.00	Yield:	0.0%
		Avg. Daily Volume:	12,602


#### RBC Estimates

FY Dec	2013A	2014E	2015E	2016E
Revenue	16.9	18.2	18.0	18.1
EPS, Ops Diluted	(6.84)	(3.88)	(2.47)	(2.02)
P/E	NM	NM	NM	NM
Revenue	Q1	Q2	Q3	Q4
2014	4.7A	4.6A	4.4A	4.5E
2015	4.5E	4.5E	4.5E	4.5E
EPS, Ops Diluted				
2014	(3.65)A	(0.98)A	(0.45)A	(0.58)E
2015	(0.56)E	(0.59)E	(0.62)E	(0.70)E

EPS, Ops Diluted: Basic shares used when EPS are negative.  
All values in USD unless otherwise noted.

**Target/Upside/Downside Scenarios**

Exhibit 1: SCYNEXIS Inc.



Source: Bloomberg and RBC Capital Markets estimates for Upside/Downside/Target

**Target price/base case**

We value SCYX at \$18 per share, which includes US and ROW sales of SCY-078. We assign a probability of success of 65% and a value of ~\$7 per share to the US and \$11 per share to the ROW opportunity. We assume a US launch in 2019 and an ROW launch in 2020. Currently, we assume that SCYX will sell SCY-078 in the US and a partner will commercialize these compounds outside the US. We forecast peak SCY-078 sales of \$300-400MM in the US and \$1.0-1.4B in the ROW

**Upside scenario**

Our upside scenario at \$35 per share, includes ~\$17 per share in value for the US opportunity and ~\$18 per share in value for the ROW opportunity. We forecast peak SCY-078 sales of \$600-700MM in the US and \$1.7B-\$2B in the ROW. We assign SCY-078 a 65% probability of success, a discount rate of 15%, and use a terminal growth rate of -50%

**Downside scenario**

Our downside scenario assumes that SCY-078 may not be successful clinically or commercially either because efficacy against resistant organisms was not borne out or it was not long lasting or an unexpected adverse event was seen. Under such a scenario shares would trade at roughly cash per share which is currently ~\$4

**Investment summary**

Scynexis' (SCYX) SCY-078 treats systemic fungal infections via a new mechanism of action that attacks the fungal cell wall, a validated target. These infections are serious, have high rates of mortality, and rates of resistance to current drugs are rising. All currently available drugs have limitations, which allow SCY-078 to generate an attractive value proposition. The worldwide market for systemic anti-fungals is nearly \$4B. Roughly 600,000 patients are identified with invasive fungal infections and an even higher number is treated. Phase I studies are completed for the oral version and in vitro and in vivo data shows activity in organisms both susceptible and resistant to currently approved drugs. Next up is a Phase II for the oral and a Phase I for the intravenous form with data in 2015. A Phase II/III study in resistant patients could start in 2016 and potentially provide a more rapid path to the market. SCYX essentially owns all rights to SCY-078, which is patent protected through 2030, as well as to its anti-fungal pipeline. This leaves SCYX free to commercialize the products itself, partner on a global or regional basis, and/or sell the company.

**Potential catalysts for SCYX shares**

- **Phase II data for oral SCY-078 in 2015.** Important catalyst as this will be the first time SCY-078 will be used in human patients.
- **Phase I data for intravenous SCY-078 in 2015.** Important as an intravenous does not yet exist and is needed to maximize the value of SCY-078 franchise.
- **Phase II/III trial design in 2015/2016.** A sign off from the FDA could determine the pace and potential path to the market.
- **Phase II/III trial start in 2016 and data by YE:17/ early 2018.** A Phase II/III study in drug resistant patients could be the first proof that SCY-078 can achieve in patients what it is designed to do and has shown in in vitro and in vivo models.
- **Business development activities in 2014/2015.** Non-core pipeline assets and even SCY-078 could be partnered opportunistically raising non-dilutive capital.

**Risks to our investment thesis**

- **Clinical studies for oral and intravenous SCY-078 could fail.** Expectations are based on pre-clinical and Phase I data and human studies could show a lack of efficacy or emergence of resistance.
- **Merck returned rights for SCY-078 back to SCYX.** This raises the question of whether MRK saw anything in SCY-078's clinical or commercial profile that was lacking.
- **Sales ramp of SCY-078 could lag expectations** unless rates of resistance continue to rise.
- **SCYX could fail to find a partner** outside the US for SCY-078.
- **Timelines are rapid and any delays could disappoint investors.**



## Exhibit 2: News flow

Timing	Expected News Flow	Program
Late 2014/ early 2015	Request QIDP designation for i.v. SCY-078	SCY-078
2014/2015	Potential pipeline related business development	
1H:15	Initiate Phase I study with i.v. SCY-078	SCY-078
Mid/ 2H:15	Phase I intravenous SCY-078 results	SCY-078
2015	Phase II update from oral SCY-078 step down study	SCY-078
2H:15/ 1Q:16	Phase II results from oral SCY-078 step down study	SCY-078
2016	Initiate Phase II/III i.v. to oral SCY-078 in relapsed/ refractory patients	SCY-078
YE:2016/ early 2017	Initiate Phase III study for i.v. to oral SCY-078 in 1st line patients	SCY-078
Late 2017/ early 2018	Phase II/III i.v. to oral data	SCY-078
2018	Potential NDA for SCY-078	SCY-078
YE:18/ 2019	Potential accelerated approval	SCY-078

Source: Company reports and RBC Capital Markets estimates

## Exhibit 3: Pipeline

Product	Mechanism	Stage	Indication	Partner
Afrezza	Ultra rapid-acting inhaled insulin	Approved	Type 1 and type 2 diabetes	Sanofi
MKC253	Inhaled GLP-1	Phase I completed	Type 2 diabetes	

Source: Company reports



## Valuation

We value SCYX at \$18 per share, which includes US and ROW sales of SCY-078. We assign a probability of success of 65% and a value of ~\$7 per share to the US and \$11 per share to the ROW opportunity. We assume a US launch in 2019 and an ROW launch in 2020. Currently, we assume that SCYX will sell SCY-078 in the US and a partner will commercialize these compounds outside the US. We forecast peak SCY-078 sales of \$300-400MM in the US and \$1.0-1.4B in the ROW. We currently assign no additional value to the earlier stage pipeline. Finally, we assume product sales extend into 2030 and include a terminal value based on a terminal growth rate of -50% and a discount rate of 15%

## Price target impediments

Our price target is dependent solely on the clinical, regulatory and commercial success of SCY-078. A Phase II study for SCY-078 is expected in 2014 and data expected in 2015. Failure to demonstrate efficacy or safety in the study would be a significant setback. Furthermore, any setbacks in regulatory approvals in the US or EU, delay in launch, failure to secure a partnership outside the US for SCY-078, increased competition or other limitations to the market potential of these products either due to better efficacy and/or safety outcomes or pricing pressure due to the availability of generic drugs for glaucoma, could negatively impact our valuation.

## Company description

SCYNEXIS Inc. (SCYX) SCY-078 treats systemic fungal infections via a new mechanism of action that targets the fungal cell wall. These infections are serious, kill patients, and rates of resistance to current drugs are rising, while all currently available drugs have their limitations, which is the value proposition for SCY-078. The worldwide market for systemic anti-fungals is nearly \$4B. Roughly 600,000 patients are identified with invasive fungal infections and an even higher number is treated. Phase I studies are completed for the oral version and in vitro and in vivo data shows activity in organisms both susceptible and resistant to currently approved drugs. Next up is a Phase II for the oral and a Phase I for the intravenous forms with data in 2015. A Phase II/III study in resistant patients could start in 2016 and potentially provide a more rapid path to the market. SCYX essentially owns all rights to SCY-078, which is patent protected through 2030, as well as to its anti-fungal portfolio. This leaves SCYX free to commercialize the products itself, partner on a global or regional basis, and/or sell the company.



Scynexis - Income Statement

Adnan Butt (415) 633-8588

FYE December 31

Adnan.Butt@rbccm.com

(in MM; except per share)	2013A	1Q:14A	2Q:14A	3Q:14A	4Q:14E	2014E	1Q:15E	2Q:15E	3Q:15E	4Q:15E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
<b>Revenue:</b>																			
SCY-078															24.6	46.1	68.4	91.5	115.6
Other Revenue	9.6	4.7	4.6	4.4	4.5	18.2	4.5	4.5	4.5	4.5	18.0	18.1	18.2	18.3	18.4	18.5	18.6	18.7	18.8
Total Revenue	16.9	4.7	4.6	4.4	4.5	18.2	4.5	4.5	4.5	4.5	18.0	18.1	18.2	18.3	43.0	73.1	108.7	145.7	184.2
<b>Operating expenses:</b>																			
Cost of Other Revenue	16.3	4.0	4.2	3.7	4.1	15.9	4.1	4.1	4.1	4.1	16.2	17.5	17.6	17.7	17.8	17.9	18.0	18.1	18.2
R&D	4.4	1.3	1.8	2.5	3.4	9.0	3.3	3.5	3.8	4.5	15.0	20.0	30.0	35.0	25.0	22.5	25.0	27.5	30.0
SG&A	4.4	1.2	2.3	2.0	2.0	7.5	2.0	2.0	2.0	2.0	8.0	8.5	9.0	10.0	22.5	28.8	30.0	32.5	33.1
Other	(1.0)		(0.2)			(0.2)													
Total Expenses	24.1	6.5	8.1	8.2	9.4	32.2	9.3	9.6	9.8	10.6	39.2	46.0	56.6	62.7	67.8	73.8	79.8	87.3	92.9
Operating Expense (income)	(7.2)	(1.8)	(3.5)	(3.8)	(4.9)	(14.0)	(4.8)	(5.1)	(5.3)	(6.1)	(21.2)	(27.9)	(38.4)	(44.4)	(24.7)	(0.7)	28.9	58.5	91.3
<b>Other:</b>																			
Amortization of deferred financing cost and debt discount	3.5	0.5	0.2			0.8													
Interest expense for beneficial conversion feature	10.8		0.0			0.0													
Interest expense-related party	0.9																		
Interest expense	0.2	0.0				0.0													
Derivative fair value adjustment	7.9	(2.8)	(7.3)			(10.1)													
Other income		0.0	1.4		(0.1)	1.3	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)	(0.4)	(0.6)	(0.8)
Income before Tax	(30.5)	0.4	2.2	(3.8)	(5.0)	(21.9)	(4.9)	(5.1)	(5.4)	(6.1)	(21.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	28.5	57.9	90.5
Taxes																	9.7	19.7	30.8
Net income (loss)	(30.5)	0.4	2.2	(3.8)	(5.0)	(21.9)	(4.9)	(5.1)	(5.4)	(6.1)	(21.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	18.8	38.2	59.7
Net loss to common stockholders	(46.8)	(1.2)	2.0	(3.8)	(5.0)	(21.9)	(4.9)	(5.1)	(5.4)	(6.1)	(21.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	18.8	38.2	59.7
Derivative fair value adjustment		(2.8)	(7.3)	-	-	(10.1)	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss to common stockholders (diluted)		(4.0)	(5.3)	(3.8)	(5.0)	(32.0)	(4.9)	(5.1)	(5.4)	(6.1)	(21.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	18.8	38.2	59.7
EPS, Basic (GAAP)	(\$6.84)	(\$3.65)	\$0.38	(\$0.45)	(\$0.58)	(\$3.88)	(\$0.56)	(\$0.59)	(\$0.62)	(\$0.70)	(\$2.47)	(\$2.02)	(\$2.72)	(\$3.08)	(\$1.26)	(\$0.04)	\$0.91	\$1.82	\$2.79
EPS, Diluted (GAAP)	(\$5.61)	(\$6.57)	(\$0.98)	(\$0.41)	(\$0.53)	(\$5.19)	(\$0.52)	(\$0.54)	(\$0.56)	(\$0.64)	(\$2.27)	(\$1.89)	(\$2.54)	(\$2.87)	(\$1.19)	(\$0.04)	\$0.86	\$1.70	\$2.59
Shares outstanding, Basic	6.8	0.3	5.2	8.5	8.5	5.6	8.6	8.6	8.7	8.7	8.7	13.9	14.2	14.5	19.7	20.1	20.5	21.0	21.4
Shares outstanding, Diluted	8.3	0.6	5.5	9.3	9.3	6.2	9.4	9.4	9.5	9.5	9.4	14.8	15.1	15.5	20.9	21.4	22.0	22.5	23.1
<b>Operating Ratios</b>	<b>2013A</b>	<b>1Q:14A</b>	<b>2Q:14A</b>	<b>3Q:14A</b>	<b>4Q:14E</b>	<b>2014E</b>	<b>1Q:15E</b>	<b>2Q:15E</b>	<b>3Q:15E</b>	<b>4Q:15E</b>	<b>2015E</b>	<b>2016E</b>	<b>2017E</b>	<b>2018E</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>
COGS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	10.0%	10.0%	10.0%	10.0%	10.0%
Gross Margin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	90.0%	90.0%	90.0%	90.0%	90.0%
R&D	25.9%	28.1%	39.3%	56.6%	75.1%	49.4%	72.2%	77.8%	83.3%	100.0%	83.3%	110.5%	164.8%	191.3%	58.1%	30.8%	23.0%	18.9%	16.3%
SG&A	26.0%	25.6%	48.6%	46.7%	44.4%	41.2%	44.4%	44.4%	44.4%	44.4%	44.4%	47.0%	49.5%	54.6%	52.3%	39.3%	27.6%	22.3%	18.0%
Operating Margin	-42.7%	-37.9%	-74.3%	-86.8%	-109.5%	-76.6%	-106.7%	-112.2%	-117.8%	-134.4%	-117.8%	-154.1%	-211.0%	-242.6%	-57.4%	-0.9%	26.6%	40.1%	49.6%
Taxes	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%
Net Margin	-180.7%	8.8%	48.1%	-86.8%	-110.6%	-120.1%	-107.8%	-113.3%	-118.9%	-135.6%	-118.9%	-154.7%	-211.5%	-243.2%	-57.7%	-1.2%	17.3%	26.2%	32.4%

Source: Company reports and RBC Capital Markets estimates.



## Required disclosures

### Conflicts disclosures

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors, including total revenues of the member companies of RBC Capital Markets and its affiliates, a portion of which are or have been generated by investment banking activities of the member companies of RBC Capital Markets and its affiliates.

Please note that current conflicts disclosures may differ from those as of the publication date on, and as set forth in, this report. To access current conflicts disclosures, clients should refer to <https://www.rbccm.com/GLDisclosure/PublicWeb/DisclosureLookup.aspx?entityId=1> or send a request to RBC CM Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7.

A member company of RBC Capital Markets or one of its affiliates managed or co-managed a public offering of securities for SCYNEXIS Inc. in the past 12 months.

A member company of RBC Capital Markets or one of its affiliates received compensation for investment banking services from SCYNEXIS Inc. in the past 12 months.

RBC Capital Markets, LLC makes a market in the securities of SCYNEXIS Inc..

RBC Capital Markets has provided SCYNEXIS Inc. with investment banking services in the past 12 months.

### Explanation of RBC Capital Markets Equity rating system

An analyst's 'sector' is the universe of companies for which the analyst provides research coverage. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12 months relative to the analyst's sector average. Although RBC Capital Markets' ratings of Top Pick (TP)/Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis.

#### Ratings

**Top Pick (TP):** Represents analyst's best idea in the sector; expected to provide significant absolute total return over 12 months with a favorable risk-reward ratio.

**Outperform (O):** Expected to materially outperform sector average over 12 months.

**Sector Perform (SP):** Returns expected to be in line with sector average over 12 months.

**Underperform (U):** Returns expected to be materially below sector average over 12 months.


#### Risk Rating

As of March 31, 2013, RBC Capital Markets suspends its Average and Above Average risk ratings. The **Speculative** risk rating reflects a security's lower level of financial or operating predictability, illiquid share trading volumes, high balance sheet leverage, or limited operating history that result in a higher expectation of financial and/or stock price volatility.

### Distribution of ratings

For the purpose of ratings distributions, regulatory rules require member firms to assign ratings to one of three rating categories - Buy, Hold/Neutral, or Sell - regardless of a firm's own rating categories. Although RBC Capital Markets' ratings of Top Pick(TP)/Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis (as described below).

Distribution of ratings				
RBC Capital Markets, Equity Research				
As of 31-Dec-2014				
Rating	Count	Percent	Investment Banking Serv./Past 12 Mos.	
			Count	Percent
BUY [Top Pick & Outperform]	897	52.92	290	32.33
HOLD [Sector Perform]	686	40.47	137	19.97
SELL [Underperform]	112	6.61	6	5.36



References to a Recommended List in the recommendation history chart may include one or more recommended lists or model portfolios maintained by RBC Wealth Management or one of its affiliates. RBC Wealth Management recommended lists include the Guided Portfolio: Prime Income (RL 6), the Guided Portfolio: Large Cap (RL 7), the Guided Portfolio: Dividend Growth (RL 8), the Guided Portfolio: Midcap 111 (RL 9), the Guided Portfolio: ADR (RL 10), and the Guided Portfolio: Global Equity (U.S.) (RL 11). RBC Capital Markets recommended lists include the Strategy Focus List and the Fundamental Equity Weightings (FEW) portfolios. The abbreviation 'RL On' means the date a security was placed on a Recommended List. The abbreviation 'RL Off' means the date a security was removed from a Recommended List.

## Equity valuation and risks

For valuation methods used to determine, and risks that may impede achievement of, price targets for covered companies, please see the most recent company-specific research report at <https://www.rbcinsight.com> or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7.

## Conflicts policy

RBC Capital Markets Policy for Managing Conflicts of Interest in Relation to Investment Research is available from us on request. To access our current policy, clients should refer to

<https://www.rbccm.com/global/file-414164.pdf>

or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7. We reserve the right to amend or supplement this policy at any time.

## Dissemination of research and short-term trade ideas

RBC Capital Markets endeavors to make all reasonable efforts to provide research simultaneously to all eligible clients, having regard to local time zones in overseas jurisdictions. RBC Capital Markets' equity research is posted to our proprietary website to ensure eligible clients receive coverage initiations and changes in ratings, targets and opinions in a timely manner. Additional distribution may be done by the sales personnel via email, fax, or other electronic means, or regular mail. Clients may also receive our research via third party vendors. RBC Capital Markets also provides eligible clients with access to SPARC on the Firms proprietary INSIGHT website, via email and via third-party vendors. SPARC contains market color and commentary regarding subject companies on which the Firm currently provides equity research coverage. Research Analysts may, from time to time, include short-term trade ideas in research reports and / or in SPARC. A short-term trade idea offers a short-term view on how a security may trade, based on market and trading events, and the resulting trading opportunity that may be available. A short-term trade idea may differ from the price targets and recommendations in our published research reports reflecting the research analyst's views of the longer-term (one year) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. Thus, it is possible that a subject company's common equity that is considered a long-term





'Sector Perform' or even an 'Underperform' might present a short-term buying opportunity as a result of temporary selling pressure in the market; conversely, a subject company's common equity rated a long-term 'Outperform' could be considered susceptible to a short-term downward price correction. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm generally does not intend, nor undertakes any obligation, to maintain or update short-term trade ideas. Short-term trade ideas may not be suitable for all investors and have not been tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your investment advisor or institutional salesperson for more information regarding RBC Capital Markets' research.

## Analyst certification

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by RBC. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

## Disclaimer

RBC Capital Markets is the business name used by certain branches and subsidiaries of the Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets, LLC, RBC Europe Limited, RBC Capital Markets (Hong Kong) Limited, Royal Bank of Canada, Hong Kong Branch and Royal Bank of Canada, Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. RBC Capital Markets may be restricted from publishing research reports, from time to time, due to regulatory restrictions and/or internal compliance policies. If this is the case, the latest published research reports available to clients may not reflect recent material changes in the applicable industry and/or applicable subject companies. RBC Capital Markets research reports are current only as of the date set forth on the research reports. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior consent of RBC Capital Markets.

Additional information is available on request.

### To U.S. Residents:

This publication has been approved by RBC Capital Markets, LLC (member FINRA, NYSE, SIPC), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets, LLC.

### To Canadian Residents:

This publication has been approved by RBC Dominion Securities Inc. (member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

### To U.K. Residents:

This publication has been approved by RBC Europe Limited ('RBCEL') which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ('FCA') and the Prudential Regulation Authority, in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. However, targeted distribution may be made to selected retail clients of RBC and its affiliates. RBCEL accepts responsibility for this report and its dissemination in the United Kingdom.

### To Persons Receiving This Advice in Australia:

This material has been distributed in Australia by Royal Bank of Canada - Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition





or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section 761G of the Corporations Act.

**To Hong Kong Residents:**

This publication is distributed in Hong Kong by RBC Capital Markets (Hong Kong) Limited and Royal Bank of Canada, Hong Kong Branch (both entities which are regulated by the Hong Kong Monetary Authority ('HKMA') and the Securities and Futures Commission ('SFC')). Financial Services provided to Australia: Financial services may be provided in Australia in accordance with applicable law. Financial services provided by the Royal Bank of Canada, Hong Kong Branch are provided pursuant to the Royal Bank of Canada's Australian Financial Services Licence ('AFSL') (No. 246521). RBC Capital Markets (Hong Kong) Limited is exempt from the requirement to hold an AFSL under the Corporations Act 2001 in respect of the provision of such financial services. RBC Capital Markets (Hong Kong) Limited is regulated by the HKMA and the SFC under the laws of Hong Kong, which differ from Australian laws.

**To Singapore Residents:**

This publication is distributed in Singapore by the Royal Bank of Canada, Singapore Branch, a registered entity granted offshore bank licence by the Monetary Authority of Singapore. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is not indicative of future performance. If you have any questions related to this publication, please contact the Royal Bank of Canada, Singapore Branch. Royal Bank of Canada, Singapore Branch accepts responsibility for this report and its dissemination in Singapore.

**To Japanese Residents:**

Unless otherwise exempted by Japanese law, this publication is distributed in Japan by or through RBC Capital Markets (Japan) Ltd., a registered type one financial instruments firm and/or Royal Bank of Canada, Tokyo Branch, a licensed foreign bank.

® Registered trademark of Royal Bank of Canada. RBC Capital Markets is a trademark of Royal Bank of Canada. Used under license.

Copyright © RBC Capital Markets, LLC 2015 - Member SIPC

Copyright © RBC Dominion Securities Inc. 2015 - Member CIPF

Copyright © RBC Europe Limited 2015

Copyright © Royal Bank of Canada 2015

All rights reserved